Rheumatology and Therapy

metrics 2024

Fostering breakthroughs in immunology and rheumatology.

Introduction

Rheumatology and Therapy, published by Springer, stands as a prominent open-access journal within the fields of Immunology and Allergy and Rheumatology. Since its inception in 2014, the journal has made significant contributions to advancing the understanding, diagnosis, and treatment of rheumatic diseases, garnering a solid reputation with an impact factor that reflects its rigorous peer-review process and scholarly influence. Currently ranked in the Q2 quartile for both its categories according to 2023 metrics, it occupies a significant position among its peers, standing at Rank #21 out of 73 in Medicine Rheumatology and Rank #101 out of 233 for Medicine Immunology and Allergy. The journal's scope encompasses cutting-edge research, reviews, and clinical studies that aim to bridge the gap between laboratory findings and patient care, making it an invaluable resource for researchers, clinicians, and students alike. With its commitment to open access, Rheumatology and Therapy ensures that high-quality research is available to a global audience, fostering collaboration and innovation in rheumatology and immunology. To learn more, visit their official site and explore the wealth of knowledge available.

Metrics 2024

SCIMAGO Journal Rank1.07
Journal Impact Factor2.90
Journal Impact Factor (5 years)3.60
H-Index35
Journal IF Without Self2.90
Eigen Factor0.00
Normal Eigen Factor0.75
Influence1.07
Immediacy Index0.40
Cited Half Life3.30
Citing Half Life6.00
JCI0.83
Total Documents577
WOS Total Citations1707
SCIMAGO Total Citations3869
SCIMAGO SELF Citations182
Scopus Journal Rank1.07
Cites / Document (2 Years)2.80
Cites / Document (3 Years)3.40
Cites / Document (4 Years)3.42

Metrics History

Rank 2024

Scopus

Rheumatology in Medicine
Rank #21/73
Percentile 71.23
Quartile Q2
Immunology and Allergy in Medicine
Rank #101/233
Percentile 56.65
Quartile Q2

IF (Web Of Science)

RHEUMATOLOGY
Rank 20/57
Percentile 65.80
Quartile Q2

JCI (Web Of Science)

RHEUMATOLOGY
Rank 18/57
Percentile 68.42
Quartile Q2

Quartile History

Similar Journals

RHEUMATIC DISEASE CLINICS OF NORTH AMERICA

Advancing rheumatology through impactful research.
Publisher: W B SAUNDERS CO-ELSEVIER INCISSN: 0889-857XFrequency: 4 issues/year

Rheumatic Disease Clinics of North America is a premier journal published by W B Saunders Co-Elsevier Inc, dedicated to advancing the field of rheumatology through comprehensive and impactful research. With an ISSN of 0889-857X and an E-ISSN of 1558-3163, this esteemed publication has been disseminating knowledge since its inception in 1987, and continues to guide clinicians and researchers alike through its insightful articles and case studies. Positioned in the 2023 Q2 quartile for Rheumatology, it ranks #31 out of 73 journals in the Scopus category of Medicine _ Rheumatology, reflecting a commendable impact factor and relevance in the academic community. Although it does not offer open access options, the journal ensures that subscribers have access to cutting-edge research and reviews that address contemporary challenges and advancements in rheumatic disease. With its authoritative content, Rheumatic Disease Clinics of North America serves as a vital resource for those striving to improve patient care and clinical outcomes in the ever-evolving landscape of rheumatology research.

Reumatologia

Advancing knowledge in Rheumatology and Immunology.
Publisher: TERMEDIA PUBLISHING HOUSE LTDISSN: 0034-6233Frequency: 6 issues/year

Reumatologia is a dedicated open-access journal published by TERMEDIA PUBLISHING HOUSE LTD that has been serving the global scientific community since 2005. The journal focuses on the fields of Rheumatology, Immunology, and Allergy, providing a rich platform for researchers and practitioners to share innovative findings, clinical insights, and methodologies. With its roots tracing back to the early 1960s and a steady convergence of quality content through 2024, Reumatologia has secured a place in the academic landscape, currently holding a Q4 rating in Immunology and a Q3 rating in both Immunology and Allergy and Rheumatology categories for 2023. While the journal ranks #42 out of 73 in the Medicine - Rheumatology category, its open-access model ensures that research is widely disseminated, enhancing visibility and accessibility to vital knowledge that shapes therapeutic practices. Located in Poznan, Poland, Reumatologia remains a pivotal source of credible research, fostering collaboration among academics, healthcare professionals, and students internationally.

Radiation Oncology

Elevating oncology knowledge for better patient outcomes.
Publisher: BMCISSN: Frequency: 1 issue/year

Radiation Oncology is a premier scholarly journal published by BMC, dedicated to advancing the field of oncology through innovative research and comprehensive reviews since its inception in 2005. With its Open Access model, the journal ensures that the latest findings in radiotherapy and cancer treatment are accessible to a global audience, fostering collaboration and knowledge sharing among researchers, clinicians, and healthcare professionals. The journal has garnered an impressive reputation with prestigious rankings, achieving Q1 status in Radiology, Nuclear Medicine and Imaging and Q2 in Oncology as of 2023, reflecting its significant impact on the scientific community. In the Scopus rankings, it stands proud at Rank #61 in Radiology, Nuclear Medicine and Imaging, placing it in the top 81st percentile, and Rank #112 in Oncology at the 72nd percentile. With a converged publication plan extending through 2024, Radiation Oncology remains a vital resource for those dedicated to enhancing cancer treatment methodologies and outcomes.

Arthritis & Rheumatology

Empowering Global Collaboration in Rheumatology
Publisher: WILEYISSN: 2326-5191Frequency: 12 issues/year

Arthritis & Rheumatology is a leading journal dedicated to the advancement of knowledge in the fields of rheumatology, immunology, and allergy. Published by WILEY in the United Kingdom, this prestigious journal boasts an impressive impact factor and a prominent reputation, ranking in the Q1 category across multiple disciplines, including Immunology and Rheumatology. With its high ranking of 4th out of 73 in Rheumatology and notable standings in related fields, it serves as a crucial platform for researchers, healthcare professionals, and scholars to disseminate groundbreaking findings. The journal embraces an Open Access model, enhancing the accessibility of vital research to a global audience and ensuring that knowledge dissemination is maximized. Since its inception in 2014, Arthritis & Rheumatology has been at the forefront of impactful research, fostering collaboration and innovation in tackling complex challenges within these medical disciplines. Researchers looking to explore the latest advancements and engage with cutting-edge studies in these fields will find this journal to be an essential resource.

Current Rheumatology Reviews

Pioneering insights for modern rheumatology.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1573-3971Frequency: 3 issues/year

Current Rheumatology Reviews is an esteemed journal dedicated to publishing comprehensive reviews on advancements in the field of rheumatology. Established by Bentham Science Publishers, this journal has become a vital resource for researchers, clinicians, and students seeking to stay abreast of the latest developments and therapeutic strategies from 2006 to 2024. Located in the United Arab Emirates, it caters to a global audience, delivering insights that have been pivotal in shaping clinical practices. With an impact factor reflective of its Q3 status in Rheumatology by 2023, the journal ranks #46 out of 73 in the Scopus database, positioning it in the 37th percentile in the discipline. Although it operates without open access, its high-quality content ensures that each article undergoes rigorous peer review, making the Current Rheumatology Reviews a trusted platform for disseminating critical research findings and reviews that drive forward the understanding and treatment of rheumatic diseases.

Nature Reviews Rheumatology

Unveiling the latest in rheumatic disease research.
Publisher: NATURE PORTFOLIOISSN: 1759-4790Frequency: 12 issues/year

Nature Reviews Rheumatology is a premier academic journal published by NATURE PORTFOLIO, dedicated to the field of rheumatology. With an impressive impact factor reflecting its high citation rate and relevance within the scientific community, it ranks in the Q1 category for rheumatology, showcasing its essential role in disseminating cutting-edge research and reviews. The journal serves as a vital resource for researchers, clinicians, and students alike, presenting comprehensive articles that cover the latest developments, therapeutic advancements, and emerging trends in rheumatic diseases. With access options, including open access, it ensures that valuable insights are within reach for all stakeholders in the field. Situated in the United Kingdom and intersecting with a global audience, Nature Reviews Rheumatology stands as an authoritative voice, fostering education and innovation to improve patient outcomes and enhance the understanding of rheumatological conditions.

Clinical Genitourinary Cancer

Advancing knowledge in genitourinary oncology.
Publisher: CIG MEDIA GROUP, LPISSN: 1558-7673Frequency: 6 issues/year

Clinical Genitourinary Cancer, published by CIG MEDIA GROUP, LP, is a leading journal in the fields of Oncology and Urology, with an impressive impact reflected in its quartile rankings (Q2 in Oncology and Q1 in Urology for 2023) and strong Scopus rankings (22nd in Urology and 162nd in Oncology). The journal aims to innovate and inspire new research in genitourinary malignancies, providing a platform for the latest findings in diagnosis, treatment, and patient management. With its commitment to high-quality publications since its establishment in 2005, Clinical Genitourinary Cancer serves a crucial role in advancing the understanding of these complex conditions and enhancing clinical practices. Researchers, professionals, and students in the medical community are encouraged to engage with this essential resource, which facilitates open access to pioneering studies that drive the field forward.

ANTIVIRAL THERAPY

Exploring innovative therapies for viral infections.
Publisher: SAGE PUBLICATIONS LTDISSN: 1359-6535Frequency: 8 issues/year

ANTIVIRAL THERAPY is a prominent academic journal dedicated to the field of infectious diseases and pharmacology, published by SAGE Publications Ltd in the United Kingdom. Since its inception in 1996, this journal has become an essential platform for disseminating cutting-edge research and innovative therapeutic approaches for viral infections, making significant contributions to advancements in medical science. With an HIndex indicating the quality and influence of its published work, ANTIVIRAL THERAPY holds prestigious rankings in its categories, including Q3 in Infectious Diseases and Pharmacology as of 2023. While it currently does not offer open access, the journal provides valuable insights that are crucial for researchers, healthcare professionals, and students engaged in antiviral research and treatment strategies. As it converges towards 2024, the journal continues to play a vital role in shaping the understanding and management of viral diseases, making it a critical resource for anyone involved in this important field of study.

CURRENT OPINION IN RHEUMATOLOGY

Fostering Informed Dialogue in Rheumatology
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1040-8711Frequency: 6 issues/year

Current Opinion in Rheumatology, published by Lippincott Williams & Wilkins, stands as a vital resource in the field of rheumatology. Since its inception in 1989, this prestigious journal has been at the forefront of disseminating cutting-edge research, with a notable Q1 ranking in the 2023 Rheumatology category and an impressive Scopus rank of 7 out of 73, placing it in the 91st percentile. The journal's commitment to presenting insightful reviews and critical analyses of recent advancements and treatment strategies makes it an essential read for professionals, researchers, and students dedicated to the study of rheumatic diseases. Although not an open-access journal, Current Opinion in Rheumatology continues to foster an informed dialogue within the academic community through its high-impact content, ensuring that the latest developments and practices are accessible to those at the vanguard of rheumatology research.

ADVANCES IN THERAPY

Pioneering insights in medicine and pharmacology.
Publisher: SPRINGERISSN: 0741-238XFrequency: 12 issues/year

ADVANCES IN THERAPY is a prestigious peer-reviewed journal published by SPRINGER, specializing in the diverse fields of medicine and pharmacology. Established in 1984, this influential journal has become an essential resource for researchers and professionals, boasting a commendable impact factor and categorically ranking within the Q1 quartile in both Medicine (Miscellaneous) and Medical Pharmacology as of 2023. With an impressive Scopus ranking at #52 out of 272 in the realm of medical pharmacology, it places itself in the top 81st percentile, underscoring its importance in advancing therapeutic knowledge and practices. Although the journal is not open access, it provides invaluable insights and the latest research findings in therapies that significantly impact patient care, making it a vital reference for clinicians, academicians, and students alike.